Discounted Cash Flow
Trinity Biotech Plc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $99.6m | $-100.6m | $906.0k | -101.0% | — |
| 2017 | $99.1m (-0.5%) | $-40.3m (60.0%) | $1.5m (60.2%) | -40.6% (59.8%) | — |
| 2018 | $97.0m (-2.1%) | $-22.1m (45.1%) | $6.8m (368.3%) | -22.8% (44.0%) | — |
| 2019 | $90.4m (-6.8%) | $-28.9m (-30.9%) | $5.4m (-20.5%) | -32.0% (-40.4%) | — |
| 2020 | $102.0m (12.8%) | $-6.4m (77.9%) | $23.7m (339.4%) | -6.3% (80.4%) | — |
| 2021 | $93.0m (-8.8%) | $875.0k (113.7%) | $13.2m (-44.2%) | 0.9% (115.0%) | — |
| 2022 | $74.8m (-19.6%) | $-41.0m (-4786.7%) | $-921.0k (-107.0%) | -54.8% (-5926.5%) | — |
| 2023 | $57.0m (-23.8%) | $-24.0m (41.4%) | $-12.4m (-1242.0%) | -42.2% (23.1%) | — |
| 2024 | $61.6m (8.1%) | $-31.8m (-32.4%) | $-4.6m (62.8%) | -51.6% (-22.4%) | — |
| 2025 | $43.8m (-28.9%) | $-37.2m (-16.9%) | $-6.0m (-30.9%) | -84.9% (-64.5%) | — |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.